Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

Ad Hoc

17 posts
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-08-23
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction…
NNovartis
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
Read More

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

  • 2026-08-06
Ad hoc announcement pursuant to Art. 53 LR First quarter Net sales declined -5% (cc1, -1% USD), as…
NNovartis
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Read More

Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed

  • 2026-07-28
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc1, +3% USD), with…
NNovartis
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Read More

Novartis delivered sales growth in Q2 and further advanced

  • 2026-07-28
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc1, +3% USD), with…
NNovartis
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Read More

Novartis delivered sales growth in Q2 and further advanced

  • 2026-07-24
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc1, +3% USD), with…
NNovartis
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II

  • 2026-06-11
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction…
NNovartis
Eden Wells | Novartis United States of America
Read More

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

  • 2026-02-15
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to…
NNovartis
Courtney Piron | Novartis United States of America
Read More

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

  • 2026-02-15
 Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN…
NNovartis
Eden Wells | Novartis United States of America
Read More

Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1  

  • 2026-02-15
Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating…
NNovartis
Eden Wells | Novartis United States of America
Read More

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

  • 2026-02-13
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing…
NNovartis
Eden Wells | Novartis United States of America
Read More

Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company

  • 2026-02-13
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA),…
NNovartis
Eden Wells | Novartis United States of America
Read More

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

  • 2026-02-13
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
Switzerland
www.europesays.com